SCHEMBL10501611

SCHEMBL10501611

O=c1c2ccccc2[se]n1-c1ccccc1F

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 5/20 0.66
▸ MPI P34949 2/20 0.59
▸ PHOSPHO1 Q8TCT1 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ QSOX1 O00391 1/20 0.59
▸ RGS12 O14924 1/20 0.59
▸ PMM2 O15305 1/20 0.59
▸ PLIN1 O60240 1/20 0.59
▸ GMNN O75496 1/20 0.59
▸ BBOX1 O75936 1/20 0.59
▸ ALDH1A1 P00352 1/20 0.59
▸ LMNA P02545 1/20 0.59
▸ TP53 P04637 1/20 0.59
▸ CYBB P04839 1/20 0.59
▸ BCHE P06276 1/20 0.59
▸ GLA P06280 1/20 0.59
▸ POLB P06746 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ CYP2D6 P10635 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18818123 0.82 METAP2 (0.62) METAP2
SCHEMBL10501789 0.82 METAP2 (0.71) METAP2MPIPHOSPHO1
SCHEMBL29261063 0.79 METAP2 (0.66) METAP2MPIPHOSPHO1KDM4EMEN1
SCHEMBL10501672 0.79 MPI (0.72) METAP2MPIPHOSPHO1KDM4EMEN1
SCHEMBL10502354 0.79 METAP2 (0.41) METAP2MPIPHOSPHO1KDM4EMEN1
SCHEMBL10599445 0.79 METAP2 (1.00) METAP2MPIPHOSPHO1KDM4EMEN1
SCHEMBL10501917 0.79 METAP2 (0.68) METAP2MPIPHOSPHO1KDM4EMEN1
SCHEMBL30530466 0.79 METAP2 (0.66) METAP2MPIPHOSPHO1KDM4EMEN1
SCHEMBL10501697 0.79 METAP2 (0.60) METAP2MPIPHOSPHO1KDM4EMEN1
SCHEMBL28618904 0.78 METAP2 (0.64) METAP2MPIPHOSPHO1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11053236-B2 Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents THE UNIVERSITY OF TOLEDO (US) 2021-07-06 — — US disclosed
US-20190161482-A1 SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS THE UNIVERSITY OF TOLEDO (US) 2019-05-30 — — US disclosed
WO-2017223160-A1 SUBSTITUTED ISOSELENAZOLONE ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS THE UNIVERSITY OF TOLEDO (US) 2017-12-28 — — WO disclosed
EP-0154851-B1 BENZISOSELENAZOLETHIONES,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS A. Nattermann & Cie. GmbH (DE) 1989-08-02 — — EP disclosed
US-4711961-A Benzisoselenazolethiones and process for the treatment of various diseases in humans A. NATTERMANN & CIE GMBH (DE) 1987-12-08 — — US disclosed
EP-0154851-A1 Benzisoselenazolethiones,process for their preparation and pharmaceutical products containing these compounds A. Nattermann & Cie. GmbH (DE) 1985-09-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11053236-B2 Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents AIFM1, HSPE1, COX15 METAP2 3120/4885MPI 1957/4885PHOSPHO1 1266/4885
US-20190161482-A1 SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS AIFM1, HSPE1, COX15 METAP2 3120/4885MPI 1957/4885PHOSPHO1 1266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback